The 2000HIV study: Design, multi-omics methods and participant characteristics
Even during long-term combination antiretroviral therapy (cART), people living with HIV (PLHIV) have a dysregulated immune system, characterized by persistent immune activation, accelerated immune ageing and increased risk of non-AIDS comorbidities. A multi-omics approach is applied to a large cohor...
Uloženo v:
| Vydáno v: | Frontiers in immunology Ročník 13; s. 982746 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Switzerland
Frontiers Media S.A
20.12.2022
|
| Témata: | |
| ISSN: | 1664-3224, 1664-3224 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Even during long-term combination antiretroviral therapy (cART), people living with HIV (PLHIV) have a dysregulated immune system, characterized by persistent immune activation, accelerated immune ageing and increased risk of non-AIDS comorbidities. A multi-omics approach is applied to a large cohort of PLHIV to understand pathways underlying these dysregulations in order to identify new biomarkers and novel genetically validated therapeutic drugs targets.
The 2000HIV study is a prospective longitudinal cohort study of PLHIV on cART. In addition, untreated HIV spontaneous controllers were recruited. In-depth multi-omics characterization will be performed, including genomics, epigenomics, transcriptomics, proteomics, metabolomics and metagenomics, functional immunological assays and extensive immunophenotyping. Furthermore, the latent viral reservoir will be assessed through cell associated HIV-1 RNA and DNA, and full-length individual proviral sequencing on a subset. Clinical measurements include an ECG, carotid intima-media thickness and plaque measurement, hepatic steatosis and fibrosis measurement as well as psychological symptoms and recreational drug questionnaires. Additionally, considering the developing pandemic, COVID-19 history and vaccination was recorded. Participants return for a two-year follow-up visit. The 2000HIV study consists of a discovery and validation cohort collected at separate sites to immediately validate any finding in an independent cohort.
Overall, 1895 PLHIV from four sites were included for analysis, 1559 in the discovery and 336 in the validation cohort. The study population was representative of a Western European HIV population, including 288 (15.2%)
-women, 463 (24.4%) non-whites, and 1360 (71.8%) MSM (Men who have Sex with Men). Extreme phenotypes included 114 spontaneous controllers, 81 rapid progressors and 162 immunological non-responders. According to the Framingham score 321 (16.9%) had a cardiovascular risk of >20% in the next 10 years. COVID-19 infection was documented in 234 (12.3%) participants and 474 (25.0%) individuals had received a COVID-19 vaccine.
The 2000HIV study established a cohort of 1895 PLHIV that employs multi-omics to discover new biological pathways and biomarkers to unravel non-AIDS comorbidities, extreme phenotypes and the latent viral reservoir that impact the health of PLHIV. The ultimate goal is to contribute to a more personalized approach to the best standard of care and a potential cure for PLHIV. |
|---|---|
| AbstractList | Even during long-term combination antiretroviral therapy (cART), people living with HIV (PLHIV) have a dysregulated immune system, characterized by persistent immune activation, accelerated immune ageing and increased risk of non-AIDS comorbidities. A multi-omics approach is applied to a large cohort of PLHIV to understand pathways underlying these dysregulations in order to identify new biomarkers and novel genetically validated therapeutic drugs targets.
The 2000HIV study is a prospective longitudinal cohort study of PLHIV on cART. In addition, untreated HIV spontaneous controllers were recruited. In-depth multi-omics characterization will be performed, including genomics, epigenomics, transcriptomics, proteomics, metabolomics and metagenomics, functional immunological assays and extensive immunophenotyping. Furthermore, the latent viral reservoir will be assessed through cell associated HIV-1 RNA and DNA, and full-length individual proviral sequencing on a subset. Clinical measurements include an ECG, carotid intima-media thickness and plaque measurement, hepatic steatosis and fibrosis measurement as well as psychological symptoms and recreational drug questionnaires. Additionally, considering the developing pandemic, COVID-19 history and vaccination was recorded. Participants return for a two-year follow-up visit. The 2000HIV study consists of a discovery and validation cohort collected at separate sites to immediately validate any finding in an independent cohort.
Overall, 1895 PLHIV from four sites were included for analysis, 1559 in the discovery and 336 in the validation cohort. The study population was representative of a Western European HIV population, including 288 (15.2%)
-women, 463 (24.4%) non-whites, and 1360 (71.8%) MSM (Men who have Sex with Men). Extreme phenotypes included 114 spontaneous controllers, 81 rapid progressors and 162 immunological non-responders. According to the Framingham score 321 (16.9%) had a cardiovascular risk of >20% in the next 10 years. COVID-19 infection was documented in 234 (12.3%) participants and 474 (25.0%) individuals had received a COVID-19 vaccine.
The 2000HIV study established a cohort of 1895 PLHIV that employs multi-omics to discover new biological pathways and biomarkers to unravel non-AIDS comorbidities, extreme phenotypes and the latent viral reservoir that impact the health of PLHIV. The ultimate goal is to contribute to a more personalized approach to the best standard of care and a potential cure for PLHIV. BackgroundEven during long-term combination antiretroviral therapy (cART), people living with HIV (PLHIV) have a dysregulated immune system, characterized by persistent immune activation, accelerated immune ageing and increased risk of non-AIDS comorbidities. A multi-omics approach is applied to a large cohort of PLHIV to understand pathways underlying these dysregulations in order to identify new biomarkers and novel genetically validated therapeutic drugs targets.MethodsThe 2000HIV study is a prospective longitudinal cohort study of PLHIV on cART. In addition, untreated HIV spontaneous controllers were recruited. In-depth multi-omics characterization will be performed, including genomics, epigenomics, transcriptomics, proteomics, metabolomics and metagenomics, functional immunological assays and extensive immunophenotyping. Furthermore, the latent viral reservoir will be assessed through cell associated HIV-1 RNA and DNA, and full-length individual proviral sequencing on a subset. Clinical measurements include an ECG, carotid intima-media thickness and plaque measurement, hepatic steatosis and fibrosis measurement as well as psychological symptoms and recreational drug questionnaires. Additionally, considering the developing pandemic, COVID-19 history and vaccination was recorded. Participants return for a two-year follow-up visit. The 2000HIV study consists of a discovery and validation cohort collected at separate sites to immediately validate any finding in an independent cohort.ResultsOverall, 1895 PLHIV from four sites were included for analysis, 1559 in the discovery and 336 in the validation cohort. The study population was representative of a Western European HIV population, including 288 (15.2%) cis-women, 463 (24.4%) non-whites, and 1360 (71.8%) MSM (Men who have Sex with Men). Extreme phenotypes included 114 spontaneous controllers, 81 rapid progressors and 162 immunological non-responders. According to the Framingham score 321 (16.9%) had a cardiovascular risk of >20% in the next 10 years. COVID-19 infection was documented in 234 (12.3%) participants and 474 (25.0%) individuals had received a COVID-19 vaccine.ConclusionThe 2000HIV study established a cohort of 1895 PLHIV that employs multi-omics to discover new biological pathways and biomarkers to unravel non-AIDS comorbidities, extreme phenotypes and the latent viral reservoir that impact the health of PLHIV. The ultimate goal is to contribute to a more personalized approach to the best standard of care and a potential cure for PLHIV. Even during long-term combination antiretroviral therapy (cART), people living with HIV (PLHIV) have a dysregulated immune system, characterized by persistent immune activation, accelerated immune ageing and increased risk of non-AIDS comorbidities. A multi-omics approach is applied to a large cohort of PLHIV to understand pathways underlying these dysregulations in order to identify new biomarkers and novel genetically validated therapeutic drugs targets.BackgroundEven during long-term combination antiretroviral therapy (cART), people living with HIV (PLHIV) have a dysregulated immune system, characterized by persistent immune activation, accelerated immune ageing and increased risk of non-AIDS comorbidities. A multi-omics approach is applied to a large cohort of PLHIV to understand pathways underlying these dysregulations in order to identify new biomarkers and novel genetically validated therapeutic drugs targets.The 2000HIV study is a prospective longitudinal cohort study of PLHIV on cART. In addition, untreated HIV spontaneous controllers were recruited. In-depth multi-omics characterization will be performed, including genomics, epigenomics, transcriptomics, proteomics, metabolomics and metagenomics, functional immunological assays and extensive immunophenotyping. Furthermore, the latent viral reservoir will be assessed through cell associated HIV-1 RNA and DNA, and full-length individual proviral sequencing on a subset. Clinical measurements include an ECG, carotid intima-media thickness and plaque measurement, hepatic steatosis and fibrosis measurement as well as psychological symptoms and recreational drug questionnaires. Additionally, considering the developing pandemic, COVID-19 history and vaccination was recorded. Participants return for a two-year follow-up visit. The 2000HIV study consists of a discovery and validation cohort collected at separate sites to immediately validate any finding in an independent cohort.MethodsThe 2000HIV study is a prospective longitudinal cohort study of PLHIV on cART. In addition, untreated HIV spontaneous controllers were recruited. In-depth multi-omics characterization will be performed, including genomics, epigenomics, transcriptomics, proteomics, metabolomics and metagenomics, functional immunological assays and extensive immunophenotyping. Furthermore, the latent viral reservoir will be assessed through cell associated HIV-1 RNA and DNA, and full-length individual proviral sequencing on a subset. Clinical measurements include an ECG, carotid intima-media thickness and plaque measurement, hepatic steatosis and fibrosis measurement as well as psychological symptoms and recreational drug questionnaires. Additionally, considering the developing pandemic, COVID-19 history and vaccination was recorded. Participants return for a two-year follow-up visit. The 2000HIV study consists of a discovery and validation cohort collected at separate sites to immediately validate any finding in an independent cohort.Overall, 1895 PLHIV from four sites were included for analysis, 1559 in the discovery and 336 in the validation cohort. The study population was representative of a Western European HIV population, including 288 (15.2%) cis-women, 463 (24.4%) non-whites, and 1360 (71.8%) MSM (Men who have Sex with Men). Extreme phenotypes included 114 spontaneous controllers, 81 rapid progressors and 162 immunological non-responders. According to the Framingham score 321 (16.9%) had a cardiovascular risk of >20% in the next 10 years. COVID-19 infection was documented in 234 (12.3%) participants and 474 (25.0%) individuals had received a COVID-19 vaccine.ResultsOverall, 1895 PLHIV from four sites were included for analysis, 1559 in the discovery and 336 in the validation cohort. The study population was representative of a Western European HIV population, including 288 (15.2%) cis-women, 463 (24.4%) non-whites, and 1360 (71.8%) MSM (Men who have Sex with Men). Extreme phenotypes included 114 spontaneous controllers, 81 rapid progressors and 162 immunological non-responders. According to the Framingham score 321 (16.9%) had a cardiovascular risk of >20% in the next 10 years. COVID-19 infection was documented in 234 (12.3%) participants and 474 (25.0%) individuals had received a COVID-19 vaccine.The 2000HIV study established a cohort of 1895 PLHIV that employs multi-omics to discover new biological pathways and biomarkers to unravel non-AIDS comorbidities, extreme phenotypes and the latent viral reservoir that impact the health of PLHIV. The ultimate goal is to contribute to a more personalized approach to the best standard of care and a potential cure for PLHIV.ConclusionThe 2000HIV study established a cohort of 1895 PLHIV that employs multi-omics to discover new biological pathways and biomarkers to unravel non-AIDS comorbidities, extreme phenotypes and the latent viral reservoir that impact the health of PLHIV. The ultimate goal is to contribute to a more personalized approach to the best standard of care and a potential cure for PLHIV. |
| Author | Vos, Wilhelm A. J. W. Hwandih, Talent Bock, Christoph Matzaraki, Vasiliki Verbon, Annelies van Lunzen, Jan Fröberg, Janeri Vanderkerckhove, Linos Knoll, Rainer Blaauw, Marc J. T. ter Horst, Rob van der Ven, Andre J. A. M. Weijers, Gert Blok, Willem L. Vemula, Sai V. Groenendijk, Albert L. Schultze, Joachim Fu, Jingyuan Berrevoets, Marvin A. H. Joosten, Leo A. B. Vadaq, Nadira Navas, Adriana Netea, Mihai G. Schellekens, Arnt F. A. de Vet, Sterre C. P. Meeder, Elise M. G. Zhang, Yue Stalenhoef, Janneke E. Rokx, Casper Wonderlich, Elizabeth R. Brinkman, Kees van Eekeren, Louise E. Cleophas, Maartje C. P. van der Kolk, Mike Aschenbrenner, Anna C. dos Santos, Jéssica C. de Mast, Quirijn |
| AuthorAffiliation | 9 Universitair Medisch Centrum Groningen, University of Groningen , Groningen , Netherlands 12 Systems Medicine, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) eingetragener Verein (e.V.) , Bonn , Germany 16 Medical Science Department, Sysmex Europe Societas Europaea (SE) , Norderstedt , Germany 1 Department of Internal Medicine and Infectious Diseases, Radboudumc, Radboud University , Nijmegen , Netherlands 5 Department of Psychiatry, Radboudumc, Radboud University , Nijmegen , Netherlands 20 Department of Immunology and Metabolism, Life and Medical Sciences Institute, University of Bonn , Bonn , Germany 2 Department of Internal Medicine and Infectious Diseases, OLVG , Amsterdam , Netherlands 11 Medical University of Vienna, Center for Medical Statistics, Informatics and Intelligent Systems (CeMSIIS), Institute of Artificial Intelligence , Vienna , Austria 18 Translational Medical Research, ViiV Healthcare , Brentford , United Kingdom 7 Nijmegen Institute for Scientist-Practitione |
| AuthorAffiliation_xml | – name: 10 Center for Molecular Medicine (CeMM) Research Center for Molecular Medicine of the Austrian Academy of Sciences , Vienna , Austria – name: 3 Department of Internal Medicine and Department of Medical Microbiology and Infectious diseases, Erasmus Medical Center (MC), Erasmus University , Rotterdam , Netherlands – name: 8 Medical UltraSound Imaging Center (MUSIC) Department of Medical Imaging, Radboudumc, Radboud University , Nijmegen , Netherlands – name: 15 HIV Cure Research Center, Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent University , Ghent , Belgium – name: 4 Department of Internal Medicine and Infectious Diseases, Elizabeth-Tweesteden Ziekenhuis , Tilburg , Netherlands – name: 17 Clinical Development, ViiV Healthcare , Durham, NC , United States – name: 18 Translational Medical Research, ViiV Healthcare , Brentford , United Kingdom – name: 5 Department of Psychiatry, Radboudumc, Radboud University , Nijmegen , Netherlands – name: 20 Department of Immunology and Metabolism, Life and Medical Sciences Institute, University of Bonn , Bonn , Germany – name: 2 Department of Internal Medicine and Infectious Diseases, OLVG , Amsterdam , Netherlands – name: 6 Donders Institute for Brain, Radboud University , Cognition and Behavior, Nijmegen , Netherlands – name: 12 Systems Medicine, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) eingetragener Verein (e.V.) , Bonn , Germany – name: 13 Genomics & Immunoregulation, Life & Medical Sciences (LIMES) Institute, University of Bonn , Bonn , Germany – name: 14 Platform for Single Cell Genomics and Epigenomics (PRECISE), DZNE and University of Bonn , Bonn , Germany – name: 19 Department of Medical Genetics, Iuliu Hatieganu University of Medicine and Pharmacy , Cluj-Napoca , Romania – name: 11 Medical University of Vienna, Center for Medical Statistics, Informatics and Intelligent Systems (CeMSIIS), Institute of Artificial Intelligence , Vienna , Austria – name: 9 Universitair Medisch Centrum Groningen, University of Groningen , Groningen , Netherlands – name: 1 Department of Internal Medicine and Infectious Diseases, Radboudumc, Radboud University , Nijmegen , Netherlands – name: 7 Nijmegen Institute for Scientist-Practitioners in Addiction (NISPA), Radboud University , Nijmegen , Netherlands – name: 16 Medical Science Department, Sysmex Europe Societas Europaea (SE) , Norderstedt , Germany |
| Author_xml | – sequence: 1 givenname: Wilhelm A. J. W. surname: Vos fullname: Vos, Wilhelm A. J. W. – sequence: 2 givenname: Albert L. surname: Groenendijk fullname: Groenendijk, Albert L. – sequence: 3 givenname: Marc J. T. surname: Blaauw fullname: Blaauw, Marc J. T. – sequence: 4 givenname: Louise E. surname: van Eekeren fullname: van Eekeren, Louise E. – sequence: 5 givenname: Adriana surname: Navas fullname: Navas, Adriana – sequence: 6 givenname: Maartje C. P. surname: Cleophas fullname: Cleophas, Maartje C. P. – sequence: 7 givenname: Nadira surname: Vadaq fullname: Vadaq, Nadira – sequence: 8 givenname: Vasiliki surname: Matzaraki fullname: Matzaraki, Vasiliki – sequence: 9 givenname: Jéssica C. surname: dos Santos fullname: dos Santos, Jéssica C. – sequence: 10 givenname: Elise M. G. surname: Meeder fullname: Meeder, Elise M. G. – sequence: 11 givenname: Janeri surname: Fröberg fullname: Fröberg, Janeri – sequence: 12 givenname: Gert surname: Weijers fullname: Weijers, Gert – sequence: 13 givenname: Yue surname: Zhang fullname: Zhang, Yue – sequence: 14 givenname: Jingyuan surname: Fu fullname: Fu, Jingyuan – sequence: 15 givenname: Rob surname: ter Horst fullname: ter Horst, Rob – sequence: 16 givenname: Christoph surname: Bock fullname: Bock, Christoph – sequence: 17 givenname: Rainer surname: Knoll fullname: Knoll, Rainer – sequence: 18 givenname: Anna C. surname: Aschenbrenner fullname: Aschenbrenner, Anna C. – sequence: 19 givenname: Joachim surname: Schultze fullname: Schultze, Joachim – sequence: 20 givenname: Linos surname: Vanderkerckhove fullname: Vanderkerckhove, Linos – sequence: 21 givenname: Talent surname: Hwandih fullname: Hwandih, Talent – sequence: 22 givenname: Elizabeth R. surname: Wonderlich fullname: Wonderlich, Elizabeth R. – sequence: 23 givenname: Sai V. surname: Vemula fullname: Vemula, Sai V. – sequence: 24 givenname: Mike surname: van der Kolk fullname: van der Kolk, Mike – sequence: 25 givenname: Sterre C. P. surname: de Vet fullname: de Vet, Sterre C. P. – sequence: 26 givenname: Willem L. surname: Blok fullname: Blok, Willem L. – sequence: 27 givenname: Kees surname: Brinkman fullname: Brinkman, Kees – sequence: 28 givenname: Casper surname: Rokx fullname: Rokx, Casper – sequence: 29 givenname: Arnt F. A. surname: Schellekens fullname: Schellekens, Arnt F. A. – sequence: 30 givenname: Quirijn surname: de Mast fullname: de Mast, Quirijn – sequence: 31 givenname: Leo A. B. surname: Joosten fullname: Joosten, Leo A. B. – sequence: 32 givenname: Marvin A. H. surname: Berrevoets fullname: Berrevoets, Marvin A. H. – sequence: 33 givenname: Janneke E. surname: Stalenhoef fullname: Stalenhoef, Janneke E. – sequence: 34 givenname: Annelies surname: Verbon fullname: Verbon, Annelies – sequence: 35 givenname: Jan surname: van Lunzen fullname: van Lunzen, Jan – sequence: 36 givenname: Mihai G. surname: Netea fullname: Netea, Mihai G. – sequence: 37 givenname: Andre J. A. M. surname: van der Ven fullname: van der Ven, Andre J. A. M. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36605197$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kcluFDEQhi0URBbyAFxQHznQg_eFA1IUAhkpgkvganm8zDjqbg-2Gylvj2cmRAkHfCmr6q-vSvWfgqMpTR6ANwguCJHqQ4jjOC8wxHihJBaUvwAniHPaE4zp0ZP_MTgv5Q62RxUhhL0Cx4RzyJASJ-Db7cZ3uNWulz-7Umd3_7H77EtcT--7cR5q7NMYbelGXzfJlc5MrtuaXKONWzPVzm5MNrb6HEvLldfgZTBD8ecP8Qz8-HJ1e3nd33z_ury8uOkt5az2TDnMDbJBYmWoU45YJJykxDHP7Wrlg2uRCUQYE0ZZ4pwSzghPPQyKC3IGlgeuS-ZOb3McTb7XyUS9T6S81vslB68DokhhgphElDIUpHRy5aCBXhAcaGisTwfWdl6N3lk_1WyGZ9DnlSlu9Dr91kpChYVqgHcPgJx-zb5UPcZi_TCYyae5aCx4u7UiAjbp26ezHof8NaQJ0EFgcyol-_AoQVDvfNd73_XOd33wvfWIf3psrKbGtFs3Dv_p_AOX0bOI |
| CitedBy_id | crossref_primary_10_1016_j_ebiom_2024_105407 crossref_primary_10_1097_QAD_0000000000004198 crossref_primary_10_1161_JAHA_123_030606 crossref_primary_10_3390_v16040582 crossref_primary_10_1007_s11904_024_00713_0 crossref_primary_10_1093_ofid_ofae266 crossref_primary_10_3389_fimmu_2024_1459593 crossref_primary_10_1021_acsbiomedchemau_5c00074 crossref_primary_10_1038_s41591_025_03887_1 crossref_primary_10_3390_app14177526 crossref_primary_10_1007_s13365_024_01239_2 crossref_primary_10_1111_acel_14468 crossref_primary_10_3389_fimmu_2024_1350065 crossref_primary_10_1002_brb3_70021 crossref_primary_10_1016_j_phrs_2025_107812 |
| Cites_doi | 10.1016/j.cell.2016.10.018 10.3389/fgene.2017.00084 10.1097/QAI.0000000000000842 10.1016/j.jelectrocard.2014.07.022 10.1172/JCI133935 10.2165/00003495-200666060-00004 10.3389/fimmu.2021.661990 10.1002/1097-4679(199511)51:6<768 10.1136/bmjopen-2018-022516 10.1016/j.celrep.2016.10.053 10.1016/s0022-3999(01)00296-3 10.1038/s41467-021-25949-x 10.1016/j.cell.2016.10.040 10.1093/cid/civ171 10.1136/annrheumdis-2019-216233 10.1038/s41591-021-01590-5 10.1210/clinem/dgaa356 10.1016/j.cell.2016.10.017 10.1038/s41590-021-00867-8 10.1371/journal.pntd.0009187 10.1371/journal.pbio.1002050 10.1002/eji.201948390 10.1161/CIRCULATIONAHA.107.699579 10.7554/eLife.63195 10.1371/journal.pmed.1003991 10.1371/journal.pntd.0007183 10.1161/ATVBAHA.120.314508 10.1038/s41598-021-85775-5 10.1016/j.ultrasmedbio.2015.11.004 10.2450/2015.0007-15 10.1172/jci.insight.145928 10.1016/j.amjcard.2013.09.005 10.3390/v11030200 10.1111/dom.14172 10.1177/20499361221075454 10.1161/CIRCULATIONAHA.117.033369 10.2174/1874613601408010058 10.1089/bio.2015.0104 10.1038/s41467-019-10884-9 10.1016/S2352-3018(18)30039-0 10.1111/j.1360-0443.2009.02889.x 10.1016/j.cell.2016.10.020 10.1016/j.metabol.2021.154795 10.1515/cclm-2022-0094 |
| ContentType | Journal Article |
| Copyright | Copyright © 2022 Vos, Groenendijk, Blaauw, van Eekeren, Navas, Cleophas, Vadaq, Matzaraki, dos Santos, Meeder, Fröberg, Weijers, Zhang, Fu, ter Horst, Bock, Knoll, Aschenbrenner, Schultze, Vanderkerckhove, Hwandih, Wonderlich, Vemula, van der Kolk, de Vet, Blok, Brinkman, Rokx, Schellekens, de Mast, Joosten, Berrevoets, Stalenhoef, Verbon, van Lunzen, Netea and van der Ven. Copyright © 2022 Vos, Groenendijk, Blaauw, van Eekeren, Navas, Cleophas, Vadaq, Matzaraki, dos Santos, Meeder, Fröberg, Weijers, Zhang, Fu, ter Horst, Bock, Knoll, Aschenbrenner, Schultze, Vanderkerckhove, Hwandih, Wonderlich, Vemula, van der Kolk, de Vet, Blok, Brinkman, Rokx, Schellekens, de Mast, Joosten, Berrevoets, Stalenhoef, Verbon, van Lunzen, Netea and van der Ven 2022 Vos, Groenendijk, Blaauw, van Eekeren, Navas, Cleophas, Vadaq, Matzaraki, dos Santos, Meeder, Fröberg, Weijers, Zhang, Fu, ter Horst, Bock, Knoll, Aschenbrenner, Schultze, Vanderkerckhove, Hwandih, Wonderlich, Vemula, van der Kolk, de Vet, Blok, Brinkman, Rokx, Schellekens, de Mast, Joosten, Berrevoets, Stalenhoef, Verbon, van Lunzen, Netea and van der Ven |
| Copyright_xml | – notice: Copyright © 2022 Vos, Groenendijk, Blaauw, van Eekeren, Navas, Cleophas, Vadaq, Matzaraki, dos Santos, Meeder, Fröberg, Weijers, Zhang, Fu, ter Horst, Bock, Knoll, Aschenbrenner, Schultze, Vanderkerckhove, Hwandih, Wonderlich, Vemula, van der Kolk, de Vet, Blok, Brinkman, Rokx, Schellekens, de Mast, Joosten, Berrevoets, Stalenhoef, Verbon, van Lunzen, Netea and van der Ven. – notice: Copyright © 2022 Vos, Groenendijk, Blaauw, van Eekeren, Navas, Cleophas, Vadaq, Matzaraki, dos Santos, Meeder, Fröberg, Weijers, Zhang, Fu, ter Horst, Bock, Knoll, Aschenbrenner, Schultze, Vanderkerckhove, Hwandih, Wonderlich, Vemula, van der Kolk, de Vet, Blok, Brinkman, Rokx, Schellekens, de Mast, Joosten, Berrevoets, Stalenhoef, Verbon, van Lunzen, Netea and van der Ven 2022 Vos, Groenendijk, Blaauw, van Eekeren, Navas, Cleophas, Vadaq, Matzaraki, dos Santos, Meeder, Fröberg, Weijers, Zhang, Fu, ter Horst, Bock, Knoll, Aschenbrenner, Schultze, Vanderkerckhove, Hwandih, Wonderlich, Vemula, van der Kolk, de Vet, Blok, Brinkman, Rokx, Schellekens, de Mast, Joosten, Berrevoets, Stalenhoef, Verbon, van Lunzen, Netea and van der Ven |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.3389/fimmu.2022.982746 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1664-3224 |
| ExternalDocumentID | oai_doaj_org_article_f14192315814451f88d8bd0a0e732f4f PMC9809279 36605197 10_3389_fimmu_2022_982746 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: ; |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RNS RPM ACXDI CGR CUY CVF ECM EIF IAO IEA IHR IHW IPNFZ NPM RIG 7X8 5PM |
| ID | FETCH-LOGICAL-c465t-59d26a1cf829a4d9d3c17d843d5e6cbbefde6c5713557a9c3dd97da7e4e0f9673 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 20 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000906489400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1664-3224 |
| IngestDate | Fri Oct 03 12:45:45 EDT 2025 Thu Aug 21 18:38:17 EDT 2025 Thu Sep 04 16:18:44 EDT 2025 Thu Jan 02 22:53:32 EST 2025 Tue Nov 18 22:00:36 EST 2025 Sat Nov 29 03:32:02 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | COVID-19 HIV-1 cardiovascular disease HIV extreme phenotype multi-omics HIV reservoir non-AIDS comorbidities hepatic disease |
| Language | English |
| License | Copyright © 2022 Vos, Groenendijk, Blaauw, van Eekeren, Navas, Cleophas, Vadaq, Matzaraki, dos Santos, Meeder, Fröberg, Weijers, Zhang, Fu, ter Horst, Bock, Knoll, Aschenbrenner, Schultze, Vanderkerckhove, Hwandih, Wonderlich, Vemula, van der Kolk, de Vet, Blok, Brinkman, Rokx, Schellekens, de Mast, Joosten, Berrevoets, Stalenhoef, Verbon, van Lunzen, Netea and van der Ven. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c465t-59d26a1cf829a4d9d3c17d843d5e6cbbefde6c5713557a9c3dd97da7e4e0f9673 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Reviewed by: Maria Carmen Puertas, IrsiCaixa, Spain; Asghar Abbasi, David Geffen School of Medicine, University of California, Los Angeles, United States These authors have contributed equally to this work and share first authorship This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology Edited by: Andre Luis Lacerda Bachi, Universidade Santo Amaro, Brazil |
| OpenAccessLink | https://doaj.org/article/f14192315814451f88d8bd0a0e732f4f |
| PMID | 36605197 |
| PQID | 2761979370 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_f14192315814451f88d8bd0a0e732f4f pubmedcentral_primary_oai_pubmedcentral_nih_gov_9809279 proquest_miscellaneous_2761979370 pubmed_primary_36605197 crossref_primary_10_3389_fimmu_2022_982746 crossref_citationtrail_10_3389_fimmu_2022_982746 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-12-20 |
| PublicationDateYYYYMMDD | 2022-12-20 |
| PublicationDate_xml | – month: 12 year: 2022 text: 2022-12-20 day: 20 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in immunology |
| PublicationTitleAlternate | Front Immunol |
| PublicationYear | 2022 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Namiba (B41) 2022; 9 B22 Rijnbeek (B26) 2014; 47 B46 Schirmer (B7) 2016; 167 Bjelland (B28) 2002; 52 Ter Horst (B6) 2016; 167 Grievink (B32) 2016; 14 Waldor (B3) 2015; 13 Loutfy (B42) 2014; 8 Daves (B34) 2015; 13 van der Heijden (B15) 2021; 6 Bachmann (B44) 2019; 10 Ali (B14) 2020; 22 Van de Wijer (B17) 2021; 12 Weijers (B23) 2016; 42 van der Heijden (B16) 2021; 11 B31 Aguirre-Gamboa (B8) 2016; 17 Post (B36) 2021; 15 Koeken (B19) 2020; 130 van Gils (B45) 2022; 19 Zicari (B1) 2019; 11 Curno (B40) 2016; 71 Temba (B18) 2021; 22 B39 Ter Horst (B10) 2020; 40 Boender (B24) 2018; 8 Shah (B48) 2018; 138 Li (B5) 2016; 167 Froberg (B38) 2021; 12 Pitman (B2) 2018; 5 Janssen (B13) 2021; 121 Dehghan (B27) 2014; 113 LvP (B33) 2022; 60 Linssen (B37) 2020; 9 Huang (B4) 2017; 8 Pappalardo (B9) 2016; 167 Kluck (B20) 2020; 79 de Graaf (B12) 2021; 51 van der Heijden (B11) 2020; 105 Laanani (B43) 2015; 60 D'Agostino (B25) 2008; 117 Prodjosoewojo (B35) 2019; 13 Chander (B47) 2006; 66 Patton (B29) 1995; 51 Schippers (B30) 2010; 105 Deeks (B21) 2021; 27 |
| References_xml | – volume: 167 start-page: 1111 year: 2016 ident: B6 article-title: Host and environmental factors influencing individual human cytokine responses publication-title: Cell doi: 10.1016/j.cell.2016.10.018 – volume: 8 year: 2017 ident: B4 article-title: More is better: Recent progress in multi-omics data integration methods publication-title: Front Genet doi: 10.3389/fgene.2017.00084 – volume: 71 year: 2016 ident: B40 article-title: A systematic review of the inclusion (or exclusion) of women in hiv research: From clinical studies of antiretrovirals and vaccines to cure strategies publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0000000000000842 – volume: 47 year: 2014 ident: B26 article-title: Normal values of the electrocardiogram for ages 16-90 years publication-title: J Electrocardiol doi: 10.1016/j.jelectrocard.2014.07.022 – volume: 130 year: 2020 ident: B19 article-title: Bcg vaccination in humans inhibits systemic inflammation in a sex-dependent manner publication-title: J Clin Invest doi: 10.1172/JCI133935 – volume: 66 year: 2006 ident: B47 article-title: Substance abuse and psychiatric disorders in hiv-positive patients: Epidemiology and impact on antiretroviral therapy publication-title: Drugs doi: 10.2165/00003495-200666060-00004 – volume: 12 year: 2021 ident: B17 article-title: The architecture of circulating immune cells is dysregulated in people living with hiv on long term antiretroviral treatment and relates with markers of the hiv-1 reservoir, cytomegalovirus, and microbial translocation publication-title: Front Immunol doi: 10.3389/fimmu.2021.661990 – volume: 51 year: 1995 ident: B29 article-title: Factor structure of the barratt impulsiveness scale publication-title: J Clin Psychol doi: 10.1002/1097-4679(199511)51:6<768 – volume: 8 year: 2018 ident: B24 article-title: Aids therapy evaluation in the Netherlands (Athena) national observational hiv cohort: Cohort profile publication-title: BMJ Open doi: 10.1136/bmjopen-2018-022516 – volume: 17 year: 2016 ident: B8 article-title: Differential effects of environmental and genetic factors on T and b cell immune traits publication-title: Cell Rep doi: 10.1016/j.celrep.2016.10.053 – volume: 52 start-page: 69 year: 2002 ident: B28 article-title: The validity of the hospital anxiety and depression scale. an updated literature review publication-title: J Psychosom Res doi: 10.1016/s0022-3999(01)00296-3 – volume: 12 start-page: 5621 year: 2021 ident: B38 article-title: Sars-Cov-2 mucosal antibody development and persistence and their relation to viral load and covid-19 symptoms publication-title: Nat Commun doi: 10.1038/s41467-021-25949-x – volume: 167 year: 2016 ident: B9 article-title: The human functional genomics project: Understanding generation of diversity publication-title: Cell doi: 10.1016/j.cell.2016.10.040 – volume: 60 year: 2015 ident: B43 article-title: Impact of the timing of initiation of antiretroviral therapy during primary hiv-1 infection on the decay of cell-associated hiv-DNA publication-title: Clin Infect Dis doi: 10.1093/cid/civ171 – volume: 79 year: 2020 ident: B20 article-title: Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2019-216233 – volume: 27 year: 2021 ident: B21 article-title: Research priorities for an hiv cure: International aids society global scientific strategy 2021 publication-title: Nat Med doi: 10.1038/s41591-021-01590-5 – volume: 105 year: 2020 ident: B11 article-title: Vasculometabolic and inflammatory effects of aldosterone in obesity publication-title: J Clin Endocrinol Metab doi: 10.1210/clinem/dgaa356 – volume: 167 start-page: 1099 year: 2016 ident: B5 article-title: A functional genomics approach to understand variation in cytokine production in humans publication-title: Cell doi: 10.1016/j.cell.2016.10.017 – volume: 22 start-page: 287 year: 2021 ident: B18 article-title: Urban living in healthy tanzanians is associated with an inflammatory status driven by dietary and metabolic changes publication-title: Nat Immunol doi: 10.1038/s41590-021-00867-8 – volume: 15 year: 2021 ident: B36 article-title: Infection manager system (Ims) as a new hemocytometry-based bacteremia detection tool: A diagnostic accuracy study in a malaria-endemic area of Burkina Faso publication-title: PloS Negl Trop Dis doi: 10.1371/journal.pntd.0009187 – ident: B31 – volume: 13 year: 2015 ident: B3 article-title: Where next for microbiome research publication-title: PloS Biol doi: 10.1371/journal.pbio.1002050 – ident: B39 – volume: 51 year: 2021 ident: B12 article-title: Reduced concentrations of the b cell cytokine interleukin 38 are associated with cardiovascular disease risk in overweight subjects publication-title: Eur J Immunol doi: 10.1002/eji.201948390 – volume: 117 year: 2008 ident: B25 article-title: General cardiovascular risk profile for use in primary care: The framingham heart study publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.107.699579 – volume: 9 year: 2020 ident: B37 article-title: A novel haemocytometric covid-19 prognostic score developed and validated in an observational multicentre European hospital-based study publication-title: Elife doi: 10.7554/eLife.63195 – volume: 19 year: 2022 ident: B45 article-title: Antibody responses against sars-Cov-2 variants induced by four different sars-Cov-2 vaccines in health care workers in the Netherlands: A prospective cohort study publication-title: PloS Med doi: 10.1371/journal.pmed.1003991 – volume: 13 year: 2019 ident: B35 article-title: A novel diagnostic algorithm equipped on an automated hematology analyzer to differentiate between common causes of febrile illness in southeast Asia publication-title: PloS Negl Trop Dis doi: 10.1371/journal.pntd.0007183 – volume: 40 year: 2020 ident: B10 article-title: Sex-specific regulation of inflammation and metabolic syndrome in obesity publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/ATVBAHA.120.314508 – volume: 11 start-page: 6246 year: 2021 ident: B16 article-title: Long-term treated hiv infection is associated with platelet mitochondrial dysfunction publication-title: Sci Rep doi: 10.1038/s41598-021-85775-5 – volume: 42 year: 2016 ident: B23 article-title: Quantitative ultrasound for staging of hepatic steatosis in patients on home parenteral nutrition validated with magnetic resonance spectroscopy: A feasibility study publication-title: Ultrasound Med Biol doi: 10.1016/j.ultrasmedbio.2015.11.004 – volume: 13 year: 2015 ident: B34 article-title: Sample stability for complete blood cell count using the sysmex xn haematological analyser publication-title: Blood Transfus doi: 10.2450/2015.0007-15 – volume: 6 year: 2021 ident: B15 article-title: Chronic hiv infection induces transcriptional and functional reprogramming of innate immune cells publication-title: JCI Insight doi: 10.1172/jci.insight.145928 – volume: 113 start-page: 1 year: 2014 ident: B27 article-title: Comparison of prognosis in unrecognized versus recognized myocardial infarction in men versus women >55 years of age (from the Rotterdam study) publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2013.09.005 – ident: B46 – volume: 11 start-page: 200 year: 2019 ident: B1 article-title: Immune activation, inflammation, and non-aids Co-morbidities in hiv-infected patients under long-term art publication-title: Viruses doi: 10.3390/v11030200 – ident: B22 – volume: 22 year: 2020 ident: B14 article-title: Limited impact of impaired awareness of hypoglycaemia and severe hypoglycaemia on the inflammatory profile of people with type 1 diabetes publication-title: Diabetes Obes Metab doi: 10.1111/dom.14172 – volume: 9 start-page: 20499361221075454 year: 2022 ident: B41 article-title: From presumptive exclusion towards fair inclusion: Perspectives on the involvement of women living with hiv in clinical trials, including stakeholders' views publication-title: Ther Adv Infect Dis doi: 10.1177/20499361221075454 – volume: 138 year: 2018 ident: B48 article-title: Global burden of atherosclerotic cardiovascular disease in people living with hiv: Systematic review and meta-analysis publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.117.033369 – volume: 8 start-page: 58 year: 2014 ident: B42 article-title: Recruitment of hiv-positive women in research: Discussing barriers, facilitators, and research personnel's knowledge publication-title: Open AIDS J doi: 10.2174/1874613601408010058 – volume: 14 year: 2016 ident: B32 article-title: Comparison of three isolation techniques for human peripheral blood mononuclear cells: Cell recovery and viability, population composition, and cell functionality publication-title: Biopreserv Biobank doi: 10.1089/bio.2015.0104 – volume: 10 start-page: 3193 year: 2019 ident: B44 article-title: Determinants of hiv-1 reservoir size and long-term dynamics during suppressive art publication-title: Nat Commun doi: 10.1038/s41467-019-10884-9 – volume: 5 year: 2018 ident: B2 article-title: Barriers and strategies to achieve a cure for hiv publication-title: Lancet HIV doi: 10.1016/S2352-3018(18)30039-0 – volume: 105 year: 2010 ident: B30 article-title: Measurements in the addictions for triage and evaluation (Mate): An instrument based on the world health organization family of international classifications publication-title: Addiction doi: 10.1111/j.1360-0443.2009.02889.x – volume: 167 start-page: 1125 year: 2016 ident: B7 article-title: Linking the human gut microbiome to inflammatory cytokine production capacity publication-title: Cell doi: 10.1016/j.cell.2016.10.020 – volume: 121 year: 2021 ident: B13 article-title: Understanding the increased risk of infections in diabetes: Innate and adaptive immune responses in type 1 diabetes publication-title: Metabolism doi: 10.1016/j.metabol.2021.154795 – volume: 60 year: 2022 ident: B33 article-title: Reference intervals for sysmex xn hematological parameters as assessed in the Dutch lifelines cohort publication-title: Clin Chem Lab Med doi: 10.1515/cclm-2022-0094 |
| SSID | ssj0000493335 |
| Score | 2.4389699 |
| Snippet | Even during long-term combination antiretroviral therapy (cART), people living with HIV (PLHIV) have a dysregulated immune system, characterized by persistent... BackgroundEven during long-term combination antiretroviral therapy (cART), people living with HIV (PLHIV) have a dysregulated immune system, characterized by... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 982746 |
| SubjectTerms | cardiovascular disease Carotid Intima-Media Thickness COVID-19 COVID-19 Vaccines - therapeutic use Female hepatic disease HIV Infections - drug therapy HIV Infections - epidemiology HIV-1 Homosexuality, Male Humans Immunology Longitudinal Studies Male multi-omics Multiomics non-AIDS comorbidities Prospective Studies Sexual and Gender Minorities |
| Title | The 2000HIV study: Design, multi-omics methods and participant characteristics |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36605197 https://www.proquest.com/docview/2761979370 https://pubmed.ncbi.nlm.nih.gov/PMC9809279 https://doaj.org/article/f14192315814451f88d8bd0a0e732f4f |
| Volume | 13 |
| WOSCitedRecordID | wos000906489400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1664-3224 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000493335 issn: 1664-3224 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1664-3224 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000493335 issn: 1664-3224 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwEB2VqkhcUClfaUtlJE6IUG9sx3ZvBVq1Eqw4ANqb5cS2uoimVXe3Ehd-ez12utogRC-9JFLiKNabSTITz7wH8AaXCJFJrhTehZKzRpcoaVt6JiQNOnqMS43Cn-V4rCYT_XVF6gtrwjI9cAZuP4x4CkKEGiGXVlDKqcZRS71kVeAB374x6llJpn7muJcxJvIyZszC9H6Ynp8vYj5YVe-1iqlYPfgQJb7-fwWZf9dKrnx8jjfhcR81ksM82yew5rsteJh1JH8_hXE0NsFumJPTHyQRxh6QT6k04x1JFYMl9h7PSJaLnhHbOXJp-4Lqbk7aIWvzM_h-fPTt40nZCyWULa_FvBTaVbUdtUFV2nKnHWtH0inOnPB12zQ-uLgXqMYnpNUtc05LZ6XnPtqjluw5rHcXnX8JxHvOI7a1t5zyRtaNsAop2FRDWaMoL4DeombankUcxSx-mZhNINAmAW0QaJOBLuDt8pLLTKHxv8Ef0BTLgch-nQ5EnzC9T5i7fKKA17eGNPFpwSUQ2_mLxcxU-NcGKQFpAS-yYZe3YtFrsY23ADkw-WAuwzPd9CwxcmtFdSX19n1MfgceIR5YMlPRXVifXy38K9hor-fT2dUePJATtZecPW6__Dm6AaCAAuA |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+2000HIV+study%3A+Design%2C+multi-omics+methods+and+participant+characteristics&rft.jtitle=Frontiers+in+immunology&rft.au=Vos%2C+Wilhelm+A+J+W&rft.au=Groenendijk%2C+Albert+L&rft.au=Blaauw%2C+Marc+J+T&rft.au=van+Eekeren%2C+Louise+E&rft.date=2022-12-20&rft.eissn=1664-3224&rft.volume=13&rft.spage=982746&rft_id=info:doi/10.3389%2Ffimmu.2022.982746&rft_id=info%3Apmid%2F36605197&rft.externalDocID=36605197 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon |